Last reviewed · How we verify
Vaccination of High Risk Breast Cancer Patients Lacking Identifiable Disease With GM2-KLH Conjugate Plus the Immunological Adjuvant QS21
RATIONALE: Vaccines made from GM2-KLH and given with QS21 may make the body build an immune response to and kill tumor cells. PURPOSE: Phase I trial to study the effectiveness of GM2-KLH vaccine plus QS21 in treating patients with breast cancer who have no evidence of disease.
Details
| Lead sponsor | Memorial Sloan Kettering Cancer Center |
|---|---|
| Phase | Phase 1 |
| Status | COMPLETED |
| Enrolment | 9 |
| Start date | 1998-01 |
| Completion | 2001-11 |
Conditions
- Breast Cancer
Interventions
- GM2-KLH vaccine
- QS21
Countries
United States